Clinical trial of MBX 1416 for Post-Bariatric Hypoglycemia beginsThe first participant has been dosed in MBX Biosciences’ Phase 1/2 clinical trial of MBX 1416, the company’s long-acting glucagon-like...
Phase III studies to investigate survodutide for people living with obesity and overweightBoehringer Ingelheim and Zealand Pharma have initiated three Phase III trials investigating survodutide (also known as BI 456906) for...
First patient treated with SiPore21 for sustained diabetes and obesity controlThe first patient has been treated with Sigrid Therapeutics’ SiPore21, an innovative medical device designed for sustained diabetes and...
Study links GLP-1s with serious gastrointestinal conditionsGlucagon-like peptide-1 (GLP-1) agonists are associated with an increased risk of serious medical conditions including stomach paralysis,...
T2DM diagnosis at age 30 can reduce life expectancy by up to 14 yearsAn individual diagnosed with type 2 diabetes at age 30 years could see their life expectancy fall by as much as 14 years, an...
Worldwide audit finds testosterone replacement improves glycaemic control in men for up to two yearsReal-world data from an ongoing international audit of testosterone deficiency in men with type 2 diabetes, suggests that testosterone...
Tirzepatide found to reduce body weight regardless of duration of condition and BMI before treatment4 days ago